N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1085-1095

  Lothstein, Leonard ^a   Savranskaya, Luydmila ^a   Sweatman, Trevor W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

AD 198; Bcr Abl kinase; CML; Imatinib; PKC

Indexed keywords

BCR ABL PROTEIN; CYTOCHROME C; DOXORUBICIN DERIVATIVE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYLDOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE; PROTEIN BCL 2; PROTEIN KINASE C GAMMA; STAT5 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; DRUG DERIVATIVE; MESSENGER RNA; N-BENZYLADRIAMYCIN-14-VALERATE; PIPERAZINE DERIVATIVE; PROTEIN KINASE C; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL STRAIN HL 60; CELL STRAIN K 562; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CYTOCHROMES C; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; K562 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE C; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT5 TRANSCRIPTION FACTOR;

EID: 34249898932     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.11.003     Document Type: Article

References (58)

1. Heisterkamp N., Stam K., Groffen J., de Klein A., and Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315 (1985) 758-761
2. Shaul Y. c-Abl: activation and nuclear targets. Cell Death Differ 7 (2000) 10-16
3. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and Bcr-Abl in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
4. Skorski T. Bcr/Abl regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21 (2002) 8591-8604
5. Ray S., Lu Y., Kaufmann S.H., Gustafson W.C., Karp J.E., Boldogh I., et al. Genomic mechanisms of p210 Bcr-Abl signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem 279 (2004) 35604-35615
6. O'Dwyer M.E., Mauro M.J., and Druker B.J. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 53 (2002) 369-381
7. Dorsey J.F., Cunnick J.M., Mane S.M., and Wu J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. Blood 99 (2002) 1388-1397
8. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukaemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337 (1997) 223-229
9. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
10. Kasper B., Fruehauf S., Schiedlmeier B., Buchdunger E., Ho A.D., and Zeller W.J. Favorable therapeutic index of a p210 (Bcr-Abl)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 44 (1999) 433-438
11. Cortes J., Giles F., O'Brien S., Thomas D., Garcia-Manero G., Rios M.B., et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102 (2003) 83-86
12. Shah N.P. Loss of response to imatinib: mechanisms and management. Hematol (Am Soc Hematol Educ Prog) (2005) 183-187
13. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
14. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 293 (2001) 876-880
15. Hegedus T., Orfi L., Seprodi A., Varadi A., Sarkadi B., and Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587 (2002) 318-325
16. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. Bcr-Abl independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
17. Dai Y., Rahmani M., Corey S.J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279 (2004) 34227-34239
18. Ilaria Jr. R.L. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematol (Am Soc Hematol Educ Prog) (2005) 188-194
19. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 305 (2004) 399-401
20. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
21. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
22. Roaten J.B., Kazanietz M.G., Caloca M.J., Bertics P.J., Wiepz G.J., Parrill A.L., et al. Protein kinase C inhibition by N-benzyladriamycin-14-valerate (AD 198): Structural requirements, isoform specificity and interaction with the C1-regulatory domain. Mol Cancer Ther 1 (2002) 483-492
23. 2+ influx. Anticancer Drugs 17 (2006) 495-502
24. Barrett C.M., Roaten J.B., Lewis F.L., Sweatman T.W., Israel M., and Lothstein L. Drug-induced modulation of protein kinase C (PKC) correlates with circumvention of Bcl-2-mediated inhibition of apoptosis. Mol Cancer Ther 1 (2002) 469-481
25. Lothstein L., Israel M., and Sweatman T.W. Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Resist Update 4 (2001) 169-177
26. Bilyeu J.D., Panta G.R., Cavin L.G., Barrett C.M., Turner E.J., Sweatman T.W., et al. Circumvention of Nuclear Factor κB-induced chemoresistance by cytoplasmic-targeted anthracyclines. Mol Pharmacol 65 (2004) 1-10
27. Lothstein L., Rodrigues P.J., Sweatman T.W., and Israel M. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anticancer Drugs 9 (1998) 58-66
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
29. Kawasaki E.S., Clark S.S., Coyne M.Y., Smith S.D., Champlin R., Witte O.N., et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85 (1988) 5698-5702
30. Lothstein L., Suttle D.P., Roaten J.B., Koseki Y., Israel M., and Sweatman T.W. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochem Pharmacol 60 (2000) 1621-1628
31. L expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3 (2000) 299-305
32. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11 (1997) 253
33. Raitano A.B., Halpern J.R., Hambuch T.M., and Sawyers C.L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92 (1995) 11746-11750
34. Guo F., Sigua C., Bali P., George P., Fiskus W., et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105 (2005) 1246-1255
35. Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlagel U., von Bonin M., et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
36. Grant S., Turner A., Nelms P., and Yanovich S. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-d-arabinofuranosylcytosine. Leukemia 9 (1995) 808-814
37. Scherr M., Chaturvedi A., Battmer K., Dallmann I., Schultheis B., Ganser A., et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107 (2006) 3279-3287
38. Nguyen T.K., Rahmani M., Gao N., Kramer L., Corbin A.S., Druker B.J., et al. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/Abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 12 (2006) 2239-2247
39. Yu C., Dasmahapatra G., Dent P., and Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in Bcr/Abl+ human leukemia cells. Leukemia 19 (2005) 1579-1589
40. Dai Y., Rahmani M., Pei X.Y., Dent P., and Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104 (2004) 509-518
41. Yu C., Dai Y., Dent P., and Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in Bcr/Abl+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 1 (2002) 674-682
42. von Lindern M., Parren-van Amelsvoort M., van Dijk T., Deiner E., van den Akker E., et al. Protein kinase C alpha controls erythropoietin receptor signaling. J Biol Chem 275 (2000) 34719-34727
43. Xenaki D., Pierce A., Underhill-Day N., Whetton A.D., and Owen-Lynch P.J. Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII. Cell Signal 16 (2004) 145-156
44. Goldfarb A.N., Delehanty L.L., Wang D., Racke F.K., and Hussaini I.M. Stromal inhibition of megakaryocytic differentiation correlates with blockade of signaling by protein kinase C-epsilon and ERK/MAPK. J Biol Chem 276 (2001) 29526-29530
45. Kazanietz M.G. Novel "non-kinase" phorbol ester receptors: the C1 domain connection. Mol Pharmacol 61 (2002) 759-767
46. Yu C., Krystal G., Dent P., and Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in Bcr-Abl-positive human leukemia cells. Clin Cancer Res 8 (2002) 2976-2984
47. Mikami T., Koyama T., Koyama T., Imakiire A., Yamamoto K., Furuhata M., et al. c-Jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Anticancer Res 26 (2006) 1153-1160
48. Panaretakis T., Laane E., Pokrovskaja K., Bjorklund A.C., Moustakas A., Zhivotovsky B., et al. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 16 (2005) 3821-3831
49. Yamamoto K., Ichijo H., and Korsmeyer S.J. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19 (1999) 8469-8478
50. Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23 (2004) 1889-1899
51. Kawauchi K., Ogasawara T., Yasuyama M., and Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 31 (2003) 11-17
52. Rangatia J., and Bonnet D. Transient or long-term silencing of Bcr-Abl alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 20 (2006) 68-76
53. He Y., Liu J., Durrant D., Yang H.S., Sweatman T., Lothstein L., et al. N-Benzyladriamycin-14-valerate (AD 198) induces apoptosis through protein kinase C-delta-induced phosphorylation of phospholipids scramblase 3. Cancer Res 65 (2005) 10016-10023
54. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63 (2003) 5126-5135
55. Xu Y., Voelter-Mahlknecht S., and Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-Abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 15 (2005) 169-172
56. Wu L.X., Xu J.H., Huang X.W., Zhang K.Z., Wen C.X., and Chen Y.Z. Down-regulation of p210 (Bcr/Abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacol Sin 27 (2006) 694-699
57. Sweatman T.W., Seshadri R., and Israel M. Pharmacology of N-benzyladriamycin-14-valerate in the rat. Cancer Chemother Pharmacol 43 (1999) 419-426
58. Hofmann P, Israel M, Koseki Y, Arsura M, Janik A, Sweatman TW, Lothstein L. Cardioprotective effects of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate (AD 198). J Pharmacol Exp Ther, submitted for publication.